Owners, management and financials
CVR: 38817566
Previous names: Natuzone IVS, CMC Drug Product Consulting IVS
DKK 1,439,676
Gross profit
Net result: DKK 48,574
TSMF Holding ApS (100%)
CVR · view owners
Faramarz Moshfegh
CVR · view management
Active
Founded 26 July 2017
CVR · view overview
3 employees
CVR · 2026
Name registered: CMC Drug Product Consulting ApS
CVR · 05/03/2020
View the full event history
CMC Drug Product Consulting ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 2017. The company is registered under the industry Anden teknisk rådgivning. The company was previously named CMC Drug Product Consulting IVS and Natuzone IVS. The management consists of Faramarz Moshfegh. The company is owned by TSMF Holding ApS. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK 1,439,676 and a net result of DKK 48,574 compared with DKK 81,999 the year before. Equity in the 2025 report amounted to DKK 692,225.
Source: annual report 2025, Danish Business Authority
The financial health of CMC Drug Product Consulting ApS has shown significant volatility over the past few years. Gross profit peaked at 2,739,317 DKK in 2021 but has since declined to 1,439,676 DKK in 2025, with profits fluctuating from a high of 692,314 DKK in 2021 to a loss of 666,762 DKK in 2023. The company's equity position has improved from negative 380,567 DKK in 2024 to positive 692,225 DKK in 2025, indicating a recovery. However, the lack of disclosed revenue raises concerns about overall market position and sustainability within the technical consulting industry.
AI-generated summary · Generated 13/08/2026
Virksomhedens formål er at drive farmaceutisk konsulentvirksomhed indenfor det bioteknologiske område
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 1.4 mio. | 49 t. | 913 t. | 692 t. | 2 | |
| 202401/01/2024 – 31/12/2024 | 1.5 mio. | 82 t. | 836 t. | -381 t. | 2 | |
| 202301/01/2023 – 31/12/2023 | 501 t. | -667 t. | 282 t. | -463 t. | 2 | |
| 202201/01/2022 – 31/12/2022 | 1.5 mio. | 136 t. | 608 t. | 472 t. | 2 | |
| 202101/01/2021 – 31/12/2021 | 2.7 mio. | 692 t. | 1.7 mio. | 1.3 mio. | 3 | |
| 202001/01/2020 – 31/12/2020 | 3.5 mio. | 1.9 mio. | 2.7 mio. | 1.9 mio. | 3 | |
| 201901/01/2019 – 31/12/2019 | 818 t. | 287 t. | 441 t. | 287 t. | 1 |
Compared to 1.487 companies in Anden teknisk rådgivning
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of CMC Drug Product Consulting ApS is 38817566.
CMC Drug Product Consulting ApS is owned by TSMF Holding ApS.
The management of CMC Drug Product Consulting ApS consists of Faramarz Moshfegh.
In 2025, CMC Drug Product Consulting ApS reported a gross profit of DKK 1,439,676.
CMC Drug Product Consulting ApS had 3 employees in 2026 according to the Danish CVR register.
CMC Drug Product Consulting ApS was founded on 26 July 2017.
Claim this page to add your logo and social links. Free to get started.
CMC Drug Product Consulting ApS has published its annual report for 2025. Gross profit came to DKK 1,439,676, and the net result was DKK 48,574.
CMC Drug Product Consulting ApS has published its annual report for 2024. Gross profit came to DKK 1,493,397, and the net result was DKK 81,999.
CMC Drug Product Consulting ApS has published its annual report for 2023. Gross profit came to DKK 501,218, and the net result was DKK -666,762.
CMC Drug Product Consulting ApS has published its annual report for 2022. Gross profit came to DKK 1,543,773, and the net result was DKK 135,914.
CMC Drug Product Consulting ApS has published its annual report for 2021. Gross profit came to DKK 2,739,317, and the net result was DKK 692,314.
CMC Drug Product Consulting ApS has published its annual report for 2020. Gross profit came to DKK 3,477,330, and the net result was DKK 1,892,001.
CMC Drug Product Consulting ApS has published its annual report for 2019. Gross profit came to DKK 817,658, and the net result was DKK 286,941.
On March 5, 2020, the company changed its name from CMC Drug Product Consulting IVS to CMC Drug Product Consulting ApS.
CMC Drug Product Consulting ApS has published its interim report for the period July 26, 2017 to December 31, 2018.
On August 1, 2018, the company changed its name from Natuzone IVS to CMC Drug Product Consulting IVS.
As of July 26, 2017, Faramarz Moshfegh is registered as adm. dir. of CMC Drug Product Consulting ApS.
As of July 26, 2017, TSMF Holding ApS is registered as an owner of CMC Drug Product Consulting ApS with an ownership share of 100%.
CMC Drug Product Consulting ApS was founded on July 26, 2017.
Companies in the same industry and area
CVR 32807712
CVR 45882624
CVR 42433683
CVR 46653157
CVR 29933294
